Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ping An Biomedical CoPASW -6.49%17 Debt-to-EBITDA is -0.49 as of Sep. 2025. GuruFocus rates PASW with a GF Score™ of 17/100. The stock has 3 warning signs investors should review. Among 811 Manufacturing - Apparel & Accessories companies, Ping An Biomedical Co ranks worse than 123304.44% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Ping An Biomedical Co's Debt-to-EBITDA or its related term are showing as below:
PASW'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.73 Med: 3.07 Max: 23.64
Current: -0.73
During the past 5 years, the highest Debt-to-EBITDA Ratio of Ping An Biomedical Co was 23.64. The lowest was -0.73. And the median was 3.07.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Ping An Biomedical Co Debt-to-EBITDA Related Terms
Ping An Biomedical Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Ping An Biomedical Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PASW vs DXYN, CULP, UFI: Debt-to-EBITDA Comparison
For the Textile Manufacturing subindustry, Ping An Biomedical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ping An Biomedical Co Debt-to-EBITDA vs Manufacturing - Apparel & Accessories Industry
For the Manufacturing - Apparel & Accessories industry and Consumer Cyclical sector, Ping An Biomedical Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ping An Biomedical Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Sep. 2025) EBITDA data.
Ping An Biomedical Co (PASW) has a Debt-to-EBITDA of -0.49 as of Sep. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ping An Biomedical Co. According to the industry distribution chart, Ping An Biomedical Co ranks #999999 out of 811 companies in the Manufacturing - Apparel & Accessories industry.
Is Ping An Biomedical Co's Debt-to-EBITDA too high?
Ping An Biomedical Co's current Debt-to-EBITDA is -0.49. Based on the distribution chart, Ping An Biomedical Co ranks #999999 out of 811 companies in the Manufacturing - Apparel & Accessories industry, which is in the bottom quartile relative to peers. Overall, Ping An Biomedical Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Ping An Biomedical Co's Debt-to-EBITDA compare to DXYN and CULP?
According to the Manufacturing - Apparel & Accessories industry distribution chart, Ping An Biomedical Co ranks #999999 out of 811 companies for Debt-to-EBITDA. This places Ping An Biomedical Co in the lower half of its industry. The industry median Debt-to-EBITDA is 2.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Manufacturing - Apparel & Accessories company?
The median Debt-to-EBITDA among Manufacturing - Apparel & Accessories companies is 2.72, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ping An Biomedical Co. For the Manufacturing - Apparel & Accessories industry, the median Debt-to-EBITDA is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ping An Biomedical Co's current Debt-to-EBITDA is -0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ping An Biomedical Co stock overvalued right now?
Ping An Biomedical Co (PASW) has a current Debt-to-EBITDA of -0.49. The current Debt-to-EBITDA is -0.49. Ping An Biomedical Co's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Ping An Biomedical Co (PASW), the current Debt-to-EBITDA is -0.49 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ping An Biomedical Co Ltd formerly Majestic Ideal Holdings Ltd is a Cayman Islands-based holding company, conducting operations through its PRC subsidiary, NewBrand. The group is a provider of SCM services in the apparel industry, offering solutions for a broad range of yarn products, textiles, and finished garments. Its service offerings encompass every key aspect of the supply chain of textile products, such as market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management. The group has two reportable segments, yarns and finished garments. The majority of its revenue is generated from the sale of yarns, including pure cashmere and cashmere-mix yarn, merino wool, cotton, and fancy yarn.
17GF Score
Get the complete analysis for PASW
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PASW has been successfully added to your 
